

# Seizures Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/S3F83B00BCF0EN.html>

Date: May 2024

Pages: 132

Price: US\$ 6,499.00 (Single User License)

ID: S3F83B00BCF0EN

## Abstracts

The 7 major seizures markets reached a value of US\$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 4.9 Billion by 2034, exhibiting a growth rate (CAGR) of 4.17% during 2024-2034.

The seizures market has been comprehensively analyzed in IMARC's new report titled "Seizures Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Seizures are sudden, abnormal episodes of electrical activity in the brain that can cause a wide range of physical and mental symptoms. They result from a temporary disruption in the normal functioning of brain cells, leading to an abnormal surge of electrical impulses. Some of the common indications include loss of consciousness or altered awareness, muscle contractions or convulsions, sensory changes, emotional or behavioral changes, etc. Diagnosing seizures involves a comprehensive evaluation by healthcare professionals, typically including a detailed medical history, physical examination, and diagnostic tests. The medical history helps to identify the nature of the seizures, their frequency, duration, and associated symptoms. A neurological exam assesses cognitive function, reflexes, and coordination. Several diagnostic procedures, such as electroencephalogram (EEG), record the brain's electrical activity, thereby aiding in determining abnormal patterns characteristic of seizures. Various imaging tests, like magnetic resonance imaging (MRI) and computed tomography (CT) scans, may be performed to identify any underlying structural abnormalities. Additionally, blood tests and genetic screening are also utilized to determine potential metabolic or genetic causes.

The increasing prevalence of traumatic brain injuries resulting from accidents, falls, sports-related bruises, etc., which can disrupt brain structure and function, is primarily

driving the seizures market. In addition to this, the rising incidence of several associated risk factors, such as brain tumors, certain infections that affect the brain like meningitis, electrolyte imbalances, high fever, sleep deprivation, genetic mutations, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of antiepileptic drugs, including carbamazepine and lamotrigine, to control seizure activity, minimize the likelihood of seizure-related complications, and improve the quality of life for patients is further bolstering the market growth. Apart from this, the escalating application of vagus nerve stimulation (VNS), which involves the implantation of a device for regulating abnormal brain activity and reducing seizure frequency, is acting as another significant growth-inducing factor. Additionally, the introduction of advanced imaging techniques, such as functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG), that aid in pinpointing seizure foci and improving the precision of surgical interventions, is expected to drive the seizures market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the seizures market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for seizures and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the seizures market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the seizures market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the seizures market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current seizures marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the seizures market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the seizures market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the seizures market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of seizures across the seven major markets?

What is the number of prevalent cases (2018-2034) of seizures by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of seizures by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with seizures across the seven major markets?

What is the size of the seizures patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of seizures?

What will be the growth rate of patients across the seven major markets?

### Seizures: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for seizures drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the seizures market?

What are the key regulatory events related to the seizures market?

What is the structure of clinical trial landscape by status related to the seizures market?

What is the structure of clinical trial landscape by phase related to the seizures market?

What is the structure of clinical trial landscape by route of administration related to the seizures market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 SEIZURES - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 SEIZURES - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 SEIZURES - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 SEIZURES - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 SEIZURES - UNMET NEEDS**

## **10 SEIZURES - KEY ENDPOINTS OF TREATMENT**

## **11 SEIZURES - MARKETED PRODUCTS**

- 11.1 List of Seizures Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Lamictal (Lamotrigine) - GlaxoSmithKline
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Fycompa (Perampanel) - Eisai
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Topamax (Topiramate) - Janssen
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Epidiolex (Cannabidiol) - GW Pharmaceuticals
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Neurontin (Gabapentin) - Pfizer
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 SEIZURES - PIPELINE DRUGS**

- 12.1 List of Seizures Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 Staccato alprazolam - UCB Biopharma SRL
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status
  - 12.1.2 CVL865 - Cerevel Therapeutics
    - 12.1.2.1 Drug Overview
    - 12.1.2.2 Mechanism of Action
    - 12.1.2.3 Clinical Trial Results
    - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 EQU 001 - Equilibre Biopharmaceuticals
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 XEN1101 - Xenon Pharmaceuticals
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status
- 12.1.5 NBI-921352 - Neurocrine Biosciences
  - 12.1.5.1 Drug Overview
  - 12.1.5.2 Mechanism of Action
  - 12.1.5.3 Clinical Trial Results
  - 12.1.5.4 Safety and Efficacy
  - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. SEIZURES - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. SEIZURES – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

### **15 SEIZURES - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Seizures - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)

- 15.2.2 Seizures - Market Size by Therapies
  - 15.2.2.1 Market Size by Therapies (2018-2023)
  - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Seizures - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Seizures - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Seizures - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Seizures - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Seizures - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Seizures - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Seizures - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Seizures - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Seizures - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Seizures - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Seizures - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Seizures - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Seizures - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)

- 15.7.2 Seizures - Market Size by Therapies
  - 15.7.2.1 Market Size by Therapies (2018-2023)
  - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Seizures - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Seizures - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Seizures - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Seizures - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Seizures - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Seizures - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Seizures - Access and Reimbursement Overview

## **16 SEIZURES - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 SEIZURES MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 SEIZURES MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Seizures Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/S3F83B00BCF0EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S3F83B00BCF0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

